<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493597</url>
  </required_header>
  <id_info>
    <org_study_id>EC 7/5/36</org_study_id>
    <nct_id>NCT00493597</nct_id>
  </id_info>
  <brief_title>Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis</brief_title>
  <official_title>Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of In-stent Restenosis After Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinically relevant in stent restenosis occurs in 5-10% of the non-diabetic patients treated&#xD;
      with a coronary bare metal stent. Recent research has identified endothelial progenitor cells&#xD;
      as well as dendritic cells as components of neointima. Numerical and functional evaluation of&#xD;
      endothelial progenitor and dendritic cells at the time of coronary stent implantation is&#xD;
      assessed and the relation with clinical and/or angiographic restenosis at 6 months post-stent&#xD;
      implantation is evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 26, 2020</completion_date>
  <primary_completion_date type="Actual">October 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">124</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Restenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non-diabetic patients scheduled for PCI with a single bare metal stent in a significant de&#xD;
        novo coronary lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years old&#xD;
&#xD;
          -  Scheduled for PCI&#xD;
&#xD;
          -  Candidate for CABG if necessary&#xD;
&#xD;
          -  Clinical evidence of ischemic heart disease and/or abnormal functional study&#xD;
&#xD;
          -  New native coronary artery lesion &gt;50%-&lt;100% stenosis&#xD;
&#xD;
          -  Lesion length&lt;30 mm, treatment with a single bare metal stent planned&#xD;
&#xD;
          -  Reference diameter 2.5-3.5 mm&#xD;
&#xD;
          -  Informed consent explained, red, understood and signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, birth or lactation period &lt;6 months ago&#xD;
&#xD;
          -  Women of childbearing age who do not intend to use accepted anticonceptive measures or&#xD;
             who wish to get pregnant&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  Acute myocardial infarction (ST-elevation, Q-wave evolution or CK-MB &gt;2x upper limit&#xD;
             of normal)in the past month&#xD;
&#xD;
          -  Contra-indication to PCI&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Planned drug eluting stent implantation&#xD;
&#xD;
          -  Total occlusion (TIMI 0 or 1)&#xD;
&#xD;
          -  Ostial localisation (&lt;3.0 mm of the coronary ostium) of the lesion&#xD;
&#xD;
          -  Bifurcational lesion with side branch &gt;2.0 mm or side branch which will be recanalised&#xD;
             at occlusion due to PCI&#xD;
&#xD;
          -  Lesion in arterial or venous bypass or anastomosis with coronary&#xD;
&#xD;
          -  Angiographic contra-indication to IVUS&#xD;
&#xD;
          -  Severe renal insufficiency (creatinine clearance &lt;30 mL/')&#xD;
&#xD;
          -  Severe hepatic insufficiency&#xD;
&#xD;
          -  Systemic inflammatory pathology of any kind&#xD;
&#xD;
          -  Uncorrected hyperthyreosis&#xD;
&#xD;
          -  Hematologic or other malignancy, prior radio- or chemotherapy&#xD;
&#xD;
          -  Severe peripheral artery disease (accesproblem via groin)&#xD;
&#xD;
          -  Use of corticostero√Øds or immune suppression therapy&#xD;
&#xD;
          -  Contrastallergy&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Participation in other clinical study which has not ended yet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E Haine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Steven Haine</investigator_full_name>
    <investigator_title>Dr.S.Haine</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Restenosis</keyword>
  <keyword>EPC</keyword>
  <keyword>DC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

